Beyond Viral Load: Understanding BKV-Specific T-Cell Immunity After Kidney Transplantation

October 7, 2026 - Lenexa, KS, USA

BK polyomavirus, commonly referred to as BK virus or BKV, may present a persistent clinical challenge following kidney transplantation. Although primary infection typically occurs during childhood and is usually asymptomatic, BKV can establish lifelong latency in the urogenital tract. In the setting of post-transplant immunosuppression, the virus may reactivate and begin replicating, potentially contributing to BK polyomavirus-associated nephropathy, allograft dysfunction and, in some cases, graft loss.¹

The clinical balance between viral control and rejection risk

Immunosuppressive therapy is intended to reduce the risk of immune-mediated rejection after kidney transplantation. At the same time, suppression of cellular immunity may limit the body’s ability to control latent viral infections, including BKV.

When clinically significant BKPyV-DNAemia develops, reduction of immunosuppression is the primary management strategy recommended by international consensus guidelines.¹ This approach is intended to permit recovery of antiviral immune function, but it requires careful clinical judgment. Reducing immunosuppression may support immune control of BKV, while potentially increasing the risk of rejection or other immune-mediated allograft injury.

The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation recommend regular screening for plasma BKPyV-DNAemia to help facilitate early intervention. The guidelines also recognize that BKV-specific cellular immune responses may be associated with control of viral replication and represent a developing area of immune monitoring¹

What viral load can tell us

Quantitative polymerase chain reaction, or PCR, may provide a direct measurement of viral DNA in a patient specimen. Serial PCR results can help indicate whether BKV replication is emerging, increasing, remaining stable or declining over time.

This information makes quantitative PCR an important component of BKV surveillance and monitoring. Trends may be more informative than an isolated value because they can provide a longitudinal view of viral kinetics. The consensus guidelines recommend monthly plasma screening through month nine following kidney transplantation, followed by screening every three months through two years post-transplant for adults and three years for pediatric recipients.¹

Persistent or increasing BKPyV-DNAemia may indicate that viral replication is not adequately controlled. Declining viral load, particularly when sustained across serial measurements, may indicate improving control. However, PCR does not directly measure the immune response responsible for that control.

What T-cell immune monitoring may add

Control of BKV may depend substantially on cell-mediated immunity. Both CD4+ and CD8+ T cells may participate in antiviral immune responses, although their functions are not identical.

CD4+ T cells may help coordinate the immune response through cytokine signaling and support of other immune cell populations. CD8+ T cells can recognize and eliminate virus-infected cells. Following exposure to BKV antigens, responsive T cells may become activated and produce measurable cytokines.

A BKV-specific T-cell assay may evaluate whether these virus-responsive cellular populations can be detected in a patient sample. This is conceptually different from measuring viral DNA:

• Quantitative PCR may evaluate the amount of viral DNA present.
• T-cell immune monitoring may evaluate a component of the host response to the virus.

These measurements should not be viewed as interchangeable. Rather, they may provide complementary biological information. Viral load describes the current pattern of replication, while immune monitoring may provide insight into whether an antigen-specific cellular response is detectable at the time of testing.

How an antigen-specific cellular response is measured

One approach to BKV immune monitoring may involve stimulating fresh whole blood with viral peptides and evaluating whether T cells respond. The BKV inSIGHT™ T-Cell Immunity Panel uses overlapping peptides derived from the BKV VP1 and VP2 proteins to help characterize an antigen-specific cellular response.

Following stimulation, multicolor flow cytometry may be used to identify activated T cells and evaluate cytokine expression. The assay assesses activation markers and cytokines associated with the cellular response, including CD69, tumor necrosis factor alpha and interleukin-2. A nonspecific mitogen is included as a positive control to help evaluate the sample’s capacity for T-cell activation.

This type of intracellular cytokine staining may provide a functional measurement. It does not simply count the total number of circulating T cells. Instead, it may evaluate whether a subset of those cells responds after exposure to BKV-specific antigens under defined laboratory conditions.

Emerging evidence for predicting viral control

Research presented at the 2026 American Transplant Congress evaluated antigen-specific CD4+ T-cell immunity in adult kidney transplant recipients with recent-onset BK viremia.² In that study, a measurable CD4+ T-cell response to BKV VP1 and VP2 antigens may have been associated with subsequent control of viremia within approximately 30 days. Patients without a response above the study-defined cutoff may have been less likely to demonstrate viral control during the same period.²

These findings support the biological premise that antigen-specific cellular immunity may provide information about a patient’s capacity to control BKV replication. They also illustrate why the timing of immune assessment may be important. Testing during the early phase of clinically significant BKPyV-DNAemia may provide different information than testing after prolonged viremia, substantial changes to immunosuppression or resolution of viral replication.

At the same time, this evidence should be interpreted within its study context. An association with subsequent viral control does not mean that an immune response result can predict every patient’s clinical course. Transplant outcomes may be influenced by multiple interacting factors, and continued clinical assessment and serial virologic monitoring remain important.

BK polyomavirus management after kidney transplantation may require a careful balance between restoring adequate antiviral immunity and maintaining sufficient immunosuppression to protect the allograft. Quantitative PCR may provide important information about viral replication, while BKV-specific T-cell testing may evaluate a distinct aspect of the patient’s immune response.

Considering virologic and immunologic information together may support a more complete understanding of BKV-host interactions. As evidence continues to develop, BKV-specific T-cell monitoring may represent an emerging tool for studying the immune mechanisms associated with viral control and supporting a more individualized assessment of patients with BKPyV-DNAemia.

For additional scientific and technical information, review the BKV inSIGHT™ T-Cell Immunity Panel test page and related Eurofins Viracor resources.

References:

1.Kotton CN, Kamar N, Wojciechowski D, et al.; Transplantation Society International BK Polyomavirus Consensus Group. The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation. 2024;108(9):1834-1866. doi:10.1097/TP.0000000000004976. PMID: 38605438; PMCID: PMC11335089.

2. Azhar A, Abebe G, Biswas C, et al. Antigen-Specific CD4+ T Cell Immunity Predicts Control of BK Viremia. Abstract 1091. Presented at the American Transplant Congress; June 23, 2026.